Long-term safety and tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double-blind, placebo-controlled study

Trial Profile

Long-term safety and tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double-blind, placebo-controlled study

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Acronyms ODYSSEY-LONG-TERM
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Aug 2017 Results (n=3341) of a pooled post-hoc analysis from ten ODYSSEY Phase 3 (LONG TERM, HIGH FH, COMBO I, FH I, FH II, COMBO II, OPTIONS I, OPTIONS II, MONO and ALTERNATIVE) trials, published in the Diabetic Medicine.
    • 13 Jun 2017 Results of pooled analysis from ten ODYSSEY Phase 3 (LONG TERM, HIGH FH, COMBO I, FH I, FH II, COMBO II, OPTIONS I, OPTIONS II, MONO and ALTERNATIVE) trials presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top